Advancements in molecular diagnostics can prevent unnecessary surgical procedures, reducing healthcare costs and improving patients’ wellbeing.
In the United States, doctors perform approximately 25,000 unnecessary thyroid surgeries annually. Following the discovery of a lump in the throat, doctors typically recommend removal before receiving results of fine needle aspiration (FNA), isolating the risk of cancer. More often than not, FNA results for cancer are negative, leaving the patient with a long-term need for daily thyroid pills nonetheless.
Molecular diagnostic tests are the solution to this problem. Companies such as Veracyte VCYT , Cepheid CPHD, Myriad Genetics Inc. BIIB , and Hoffman-La Roche RHHBY are among the leaders in molecular medicine.
In the place of surgery, Veracyte’s Afirma test genetically analyzes the tissue from the thyroid FNA and in a few hours determines with 95% accuracy if it is cancerous. As illustrated below, the lifetime costs associated with unnecessary surgery and a lifetime of thyroid medication are more than four times greater than the $4,275 cost of an Afirma test.
This inefficiency has a tremendous economic toll. In the US the lifetime cost, including post-surgery medication, incurred by people who undergo unnecessary thyroid surgeries each year is approximately $500 million. As shown below, it would cost approximately 20% of that amount to test all of these individuals to determine the need for surgery.
These large scale systemic wastes are not unique to thyroid nodules. As with thyroid cancer, FNA tests are used for many other cancers, including breast and prostate. Consequently, the size of the molecular diagnostics market is likely to be billions of dollars, perhaps tens of billions, potentially saving the healthcare system hundreds of billions of dollars in unnecessary surgeries and drugs.
The information provided is for informational purposes only. It does not constitute any form of advice or recommendation to buy or sell any securities mentioned. It is intended only to provide observations and views of the author(s) at the time of writing, both of which are subject to change at any time without prior notice. Certain of the statements contained herein are statements of future expectations and other forward-looking statements that are based on ARK's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Past performance is no guarantee of future results. Equities may decline in value due to both real and perceived general market, economic, and industry conditions. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, click here.